Scientist Forged Ethical Reviews for CRISPRed Babies

He Jiankui could face charges after an investigation finds he used techniques prohibited in China to edit the genes of twin girls.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

ABOVE: He Jiankui
WIKIMIEDIA, THE HE LAB

He Jiankui, a researcher who announced in November that he had edited the genes of twin baby girls when they were embryos, fabricated ethics documents and violated government regulations in China, Xinhua News Agency reports today (January 21). Those are among a number of troubling conclusions to come out of a government investigation into He’s use of CRISPR to alter the embryos’ genomes during IVF.

“The report will hopefully set an example with appropriate legal and punitive actions to reassure the public and scientific community,” Yalda Jamshidi, a genomics expert at the University of London, tells Reuters.

The investigation, commissioned by Guangdong province, accuses He of pursuing “fame and fortune” and of “evading supervision,” according to Xinhua, and he could face charges for the “suspected crimes” of violating laws surrounding reproductive assistance.

Bucking a near-consensus within the scientific and ethics communities that CRISPR should ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies